カテゴリ： GlobalData, アメリカ, 企業調査

Pfizer Inc (PFE)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Pfizer Inc (PFE) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011028
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：189
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, infusion systems, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the US, Canada, Latin America, Asia, Japan, South Korea, New Zealand, Australia, Finland, Scandinavian countries, Africa, the Middle East and Turkey. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Pfizer Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Pfizer Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Pfizer Inc, Medical Equipment, Deal Details 17
Venture Financing 17
Neuronetics Raises USD15 Million in Series G Round of Financing 17
Cordex Systems Raises Funds in Series A Financing 19
Advanced MR Analytics Raises USD9 Million in Venture Financing 21
Molecular Stethoscope Raises USD8.2 Million in Seed Financing 22
RefleXion Medical Raises Additional USD6 Million in Series B Financing 23
RefleXion Medical Raises USD46 Million in Series B Financing 24
UE LifeSciences to Raise USD0.1 Million in Seed Financing 25
RefleXion Medical Raises US$11.6 Million In Series A Round 27
NeuMoDx Raises US$21 Million In Series B Financing 28
Nodality Raises US$15 Million In Venture Financing Round 29
InnoPharma Secures US$15 Million In Series A Financing Round 30
Neuronetics Secures US$30 Million In Series E Financing 31
U-Systems Secures US$6.5 Million In Venture Financing Round 33
Partnerships 34
Mayne Pharma Enters into Licensing Agreement with Mithra Pharma 34
Pfizer Enters into Licensing Agreement with Scripps Research Institute 35
Pfizer Enters into Licensing Agreement with Pelago Bioscience 36
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 37
pSivida Amends Licensing Agreement With Pfizer 38
Mirth Enters Into Licensing Agreement With Pfizer Health Solutions 39
InSphero Enters into Agreement with Pfizer 40
Molecular Stethoscope Enters into Research Agreement with Pfizer 41
Iatric Systems Enters into Agreement with Hospira 42
Pfizer Enters into Distribution Agreement Adhezion Biomedical 43
Pfizer Enters into Research Agreement with International Business Machines 44
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 45
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 46
Merck and Pfizer Enters into Agreement with Dako 47
Pfizer Enters into Evaluation Agreement with BIRAD 48
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 49
Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 50
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 51
MaRS Innovation Enters Into Partnership With Pfizer 52
Dako Enters Into Agreement With Pfizer For Companion Diagnostics 53
Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 54
Humedica Enters Into Agreement With Pfizer 55
Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 56
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 57
ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 58
ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 59
Qiagen Enters Into Co-Development Agreement With Pfizer 60
Resonance Health Enters into Agreement with Pfizer 61
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 62
Abbott Labs Enters Into Licensing Agreement With Pfizer 63
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 64
Debt Offering 65
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 65
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 67
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 69
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 71
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 73
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 75
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 77
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 79
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 81
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 83
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 85
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 87
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 89
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 91
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 93
Asset Transactions 95
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 95
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 97
True Process Acquires VeriScan, Bar Code And Radio-Frequency Identification System From Hospira 99
Acquisition 100
Pfizer Acquires Hospira for USD17 Billion 100
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 102
Pfizer May Increase Bid to Acquire AstraZeneca 103
Premier Acquires TheraDoc from Hospira for USD108.6 Million 105
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 106
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 108
Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 110
Pfizer Inc – Key Competitors 112
Pfizer Inc – Key Employees 113
Pfizer Inc – Locations And Subsidiaries 115
Head Office 115
Other Locations & Subsidiaries 115
Joint Venture 138
Recent Developments 139
Strategy And Business Planning 139
Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 139
Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 140
Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation 141
Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia 143
Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts 144
Financial Announcements 145
Oct 31, 2017: Pfizer Reports Third-Quarter 2017 Results 145
Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 148
May 02, 2017: Pfizer Reports First-Quarter 2017 Results 152
Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 156
Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 161
Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results 165
May 03, 2016: Pfizer Reports First-Quarter 2016 Results 169
Feb 02, 2016: Pfizer Reports Fourth-Quarter And Full-Year 2015 Results Provides 2016 Financial Guidance 173
Corporate Communications 178
Nov 13, 2017: Pfizer Names Albert Bourla Chief Operating Officer 178
Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 180
Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer’s Board of Directors 181
Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 182
Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research 183
Feb 08, 2016: Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction 184
Legal and Regulatory 185
Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For $784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program 185
Mar 22, 2016: Geisinger Health System receives accreditation from the Association for the Accreditation of Human Research Protection Programs 187
Other Significant Developments 188
Aug 17, 2017: OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry 188
Appendix 189
Methodology 189
About GlobalData 189
Contact Us 189
Disclaimer 189

List of Tables
Pfizer Inc, Medical Equipment, Key Facts, 2016 2
Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Pfizer Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Pfizer Inc, Deals By Market, 2011 to YTD 2017 11
Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Neuronetics Raises USD15 Million in Series G Round of Financing 17
Cordex Systems Raises Funds in Series A Financing 19
Advanced MR Analytics Raises USD9 Million in Venture Financing 21
Molecular Stethoscope Raises USD8.2 Million in Seed Financing 22
RefleXion Medical Raises Additional USD6 Million in Series B Financing 23
RefleXion Medical Raises USD46 Million in Series B Financing 24
UE LifeSciences to Raise USD0.1 Million in Seed Financing 25
RefleXion Medical Raises US$11.6 Million In Series A Round 27
NeuMoDx Raises US$21 Million In Series B Financing 28
Nodality Raises US$15 Million In Venture Financing Round 29
InnoPharma Secures US$15 Million In Series A Financing Round 30
Neuronetics Secures US$30 Million In Series E Financing 31
U-Systems Secures US$6.5 Million In Venture Financing Round 33
Mayne Pharma Enters into Licensing Agreement with Mithra Pharma 34
Pfizer Enters into Licensing Agreement with Scripps Research Institute 35
Pfizer Enters into Licensing Agreement with Pelago Bioscience 36
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 37
pSivida Amends Licensing Agreement With Pfizer 38
Mirth Enters Into Licensing Agreement With Pfizer Health Solutions 39
InSphero Enters into Agreement with Pfizer 40
Molecular Stethoscope Enters into Research Agreement with Pfizer 41
Iatric Systems Enters into Agreement with Hospira 42
Pfizer Enters into Distribution Agreement Adhezion Biomedical 43
Pfizer Enters into Research Agreement with International Business Machines 44
Medivation and NanoString Technologies Enters into Partnership With Astellas Pharma 45
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 46
Merck and Pfizer Enters into Agreement with Dako 47
Pfizer Enters into Evaluation Agreement with BIRAD 48
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 49
Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 50
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 51
MaRS Innovation Enters Into Partnership With Pfizer 52
Dako Enters Into Agreement With Pfizer For Companion Diagnostics 53
Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 54
Humedica Enters Into Agreement With Pfizer 55
Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 56
Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 57
ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 58
ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 59
Qiagen Enters Into Co-Development Agreement With Pfizer 60
Resonance Health Enters into Agreement with Pfizer 61
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 62
Abbott Labs Enters Into Licensing Agreement With Pfizer 63
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 64
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 65
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 67
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 69
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 71
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 73
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 75
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 77
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 79
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 81
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 83
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 85
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 87
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 89
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 91
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 93
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 95
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 97
True Process Acquires VeriScan, Bar Code And Radio-Frequency Identification System From Hospira 99
Pfizer Acquires Hospira for USD17 Billion 100
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 102
Pfizer May Increase Bid to Acquire AstraZeneca 103
Premier Acquires TheraDoc from Hospira for USD108.6 Million 105
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 106
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 108
Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 110
Pfizer Inc, Key Competitors 112
Pfizer Inc, Key Employees 113
Pfizer Inc, Subsidiaries 115
Pfizer Inc, Joint Venture 138

★海外企業調査レポート[Pfizer Inc (PFE)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • 3E sanv：企業の戦略的SWOT分析
    3E sanv - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Rigel Pharmaceuticals Inc (RIGL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • Fusion Telecommunications International, Inc.：企業のM&A・事業提携・投資動向
    Fusion Telecommunications International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fusion Telecommunications International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • Cell Therapy Catapult Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market …
  • Wanbury Ltd (WANBURY)：企業の財務・戦略的SWOT分析
    Summary Wanbury Ltd (Wanbury) is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients. The company offers products such as Cpink tablet, rabiplus capsule, cdense tablets, gems, adtrol-plus soft gelatin capsule, folinine softule, cheer capsule and cheer syrup. It inc …
  • Cadence Biomedical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cadence Biomedical Inc (Cadence), formerly Empowering Engineering Technologies Corp is a medical device company that provides mobility products. The company offers product such as Kickstart walking system. Its product allows users to regain the ability and endurance to stand, walk and return …
  • Tanzania Electric Supply Co Ltd-エネルギー分野：企業M&A・提携分析
    Summary Tanzania Electric Supply Co Ltd (TANESCO), formerly Tanganyika Electric Supply Company Limited, is a government-owned integrated power company. The company’s operations are regulated by the Ministry of Energy and Minerals. It generates, transmits, distributes and supplies electricity. TANESC …
  • BSN medical GmbH-医療機器分野：企業M&A・提携分析
    Summary BSN medical GmbH (BSN medical) is healthcare company specialized in compression therapy, wound care and othropedics. It manufactures and markets medical products for wound care and related vascular diseases, lumphology and non-invasive orthopedic products. The company's product line includes …
  • Tokyo Electric Power Company Holdings Incorporated (9501)-石油・ガス分野：企業M&A・提携分析
    Summary Tokyo Electric Power Company Holdings, Incorporated (TEPCO), formerly Tokyo Electric Power Company, Incorporated, is an integrated energy company. The company generates, transmits, distributes and sells electricity through its subsidiaries. It generates power from various sources such as the …
  • The Clorox Company：戦略・SWOT・企業財務分析
    The Clorox Company - Strategy, SWOT and Corporate Finance Report Summary The Clorox Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Purplebricks Group plc：企業の戦略・SWOT・財務分析
    Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report Summary Purplebricks Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Suzano Papel e Celulose SA (SUZB5)：企業の財務・戦略的SWOT分析
    Suzano Papel e Celulose SA (SUZB5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Energy XXI Gulf Coast Inc (EXXIQ)：企業の財務・戦略的SWOT分析
    Summary Energy XXI Gulf Coast Inc (Energy XXI) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include West Delta, South Timbalier, South Pass, Main Pass, and Ship Shoal. Its West Delta property is located 28 miles offshore of Grand Isle, Louis …
  • Grupa Azoty Zaklady Chemiczne Police SA (PCE)：企業の財務・戦略的SWOT分析
    Grupa Azoty Zaklady Chemiczne Police SA (PCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Brenntag Canada Inc：企業の戦略的SWOT分析
    Brenntag Canada Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Total Energy Services Inc (TOT)：石油・ガス：M&Aディール及び事業提携情報
    Summary Total Energy Services Inc (Total Energy) is an energy services company. It offers contract drilling services and rental and transportation services for equipment utilized in drilling, completion and production activities in oil and gas wells. The company also provides fabrication, sale, rent …
  • Ray Sigorta A.S.：企業の戦略・SWOT・財務情報
    Ray Sigorta A.S. - Strategy, SWOT and Corporate Finance Report Summary Ray Sigorta A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dottikon ES Holding AG (DESN)：企業の財務・戦略的SWOT分析
    Dottikon ES Holding AG (DESN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Petrogrand AB：石油・ガス：M&Aディール及び事業提携情報
    Summary Petrogrand AB (Petrogrand), formerly Malka Oil AB is an oil and gas company that acquires, explores and produces crude oil and natural gas assets. The company carries out management and refining of Russian oil assets. It holds interests in the Nizhne-Paninsky license area located in northwes …
  • Univision Communications Inc.：企業の戦略的SWOT分析
    Univision Communications Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆